

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Table I
Percentage of Cells Expressing SA- β -Gal Cells

| Cells | Φ | Doxorubicin | Taxol |
|-------|--------|-------------|-------|
| MCF7 | 2% | 24% | 13% |

Table II
Percentage of Cells Expressing SA- β -Gal in Patient Tissue After Herceptin Treatment

| Time Elapsed | Percent |
|--------------|---------|
| Day 0 | 0% |
| Day 2 | 1.5% |
| Day 14 | 26% |

Table III
Expression of p53 and p21^{CIP1/WAF1} in MCF7 Cells

Treated for 3 days with Doxorubicin

| Treatment | Cells stained for p53 (% Cells) | Cells stained for p21 ^{CIP1/WAF1} (% Cells) |
|-----------|------------------------------------|--|
| Φ | 14.43 \pm 6 | 10.61 \pm 4 |
| DOX | 23.93 \pm 7 | 50.81 \pm 6 |

Table IV

**Twenty Breast Cancer Patients Analyzed by Image Analysis
Before and After Neoadjuvant Chemotherapy**

| | P21 | P21+ |
|-------------------------|------------|-------------|
| Before treatment | 16 | 4 |
| After treatment | 7 | 13 |

FIG. 1A




FIG. 1B




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 3A



FIG. 3B




FIG. 3C

